143017-63-4

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 1,2,3,6-tetrahydro-4-(4-methoxyphenyl)-, hydrochloride is used as a reagent for the preparation of negative allosteric modulators of GluN2B. These modulators are crucial in the development of rapidly acting antidepressants, as they target the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B, which plays a significant role in modulating synaptic plasticity and neurotransmission. By inhibiting the过度兴奋 (overexcitation) of these receptors, the compound can potentially alleviate the symptoms of depression and contribute to the development of novel and more effective antidepressant medications.

Upstream product

• 6717-00-6 1-benzyl-4-(4-methoxy-phenyl)-piperidin-4-ol 
• 302924-67-0 tert-butyl 4-hydroxy-4-(4-methoxyphenyl)-1-piperidinecarboxylate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 13139-86-1 4-methoxyphenyl magnesium bromide 

Downstream Products

• 21820-71-3 5-{2-[4-(4-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl}-3-methyl-oxazolidin-2-one 
• 1026561-42-1 4-(1H-Indol-3-yl)-1-[4-(4-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butan-1-one 
• 6748-48-7 4-(4-methoxyphenyl)-piperidinehydrochloride 
• 143682-48-8 3-{4-[4-(4-Methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butyl}-1H-indole 
• 211947-93-2 2-[4-(4-Methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-1-phenyl-ethanol 
• 49797-99-1 5-{2-[4-(4-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl}-oxazolidin-2-one 

Relevant academic research and scientific papers

BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder

There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We

(R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZYL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of

Selective NR2B Antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the c

Synthesis and dopaminergic activity of some 3-(1,2,3,6-tetrahydro-1- pyridylalkyl)indoles. A novel conformational model to explain structure- activity relationships

The synthesis and dopaminergic properties of a novel type of dopamine agonist is described. The number and kind of essential structural elements differ significantly from that of the rigid apomorphine-type dopamine agonists. Using standard molecular modeling techniques, a conformational model is developed proposing a U-shaped conformation which might be energetically preferred through aromatic π-π-interactions between both of the electron rich aromatic structural elements of this class of compounds. Superimposition of conformations of the lead compound 28 with apomorphine yields a novel model explaining the atypical structure-activity relationships found in this class of indolealkylamines.